Document 32 - Assort Design

Document #32 Medical Affairs

Source: url • Audience: medical_affairs • Status: completed

Routing confidence: 90% • Candidates: Medical Affairs, R&D, Commercial

Routing reasons: The document focuses on detailed medical information about metabolic dysfunction-associated steatohepatitis (MASH) and its treatment.; It includes references to medical literature and emphasizes disease mechanisms, diagnosis, and therapeutic development.; The text highlights FDA approval of treatments and ongoing research, which is relevant to medical professionals and medical affairs rather than commercial sales or early-stage R&D.

Back to Request Back Home

Home - Madrigal Medical Professionals Contact Us Search for: Back Region United States Germany About Our Leaders Community Corporate Giving Therapeutic Focus What is MASH? Our Medicine Careers & Culture Investors & Media Leading the Fight Against MASH Our innovative research led to the first breakthrough in MASH treatment. And we’re just getting started. More About Madrigal COMPANY NEWS European Commission Grants Approval of Our Medicine. Read more Pam, patient advocate Delivering a Breakthrough Treatment Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for meta...

Show full document

Home - Madrigal Medical Professionals Contact Us Search for: Back Region United States Germany About Our Leaders Community Corporate Giving Therapeutic Focus What is MASH? Our Medicine Careers & Culture Investors & Media Leading the Fight Against MASH Our innovative research led to the first breakthrough in MASH treatment. And we’re just getting started. More About Madrigal COMPANY NEWS European Commission Grants Approval of Our Medicine. Read more Pam, patient advocate Delivering a Breakthrough Treatment Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need. Left untreated, MASH can lead to progressive liver scarring, cirrhosis, liver failure, liver cancer, need for transplant and premature mortality. Our goal is to halt or reverse liver scarring (fibrosis) and resolve MASH before patients experience the devastating complications of cirrhosis. Madrigal’s ambitious research program led to the first U.S. Food and Drug Administration (FDA)-approved treatment in MASH. Our Medicine Shining a Light on MASH Shining a Light on MASH Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), is a serious form of fatty liver disease that occurs when fat in the liver becomes toxic, damaging liver cells. The chronic and progressive nature of the disease can cause significant damage over time, including inflammation and scarring, or fibrosis. Fibrosis can progress quickly and be unpredictable, often resulting in cirrhosis and decompensated liver disease. MASH is the leading cause of liver transplantation in the U.S. for women and is expected to soon become the leading cause for men. More About MASH Careers & Culture Interested in transforming care of people living with MASH? Learn more about Madrigal’s purpose, Core Values and culture. Explore Life at Madrigal News Read More News Read More News Events View More Events View More Events References Alkhouri N, McCullough AJ. Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol (N Y). 2012;8(10):661-8. Heyens LJM, Busschots D, Koek GH, et al. Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment. Front Med (Lausanne) . 2021;8:615978. Noureddin M, Vipani A, Bresee C, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol . 2018;113(11):1649-1659. Wong RJ, Singal AK. Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019. JAMA Netw Open . 2020;3(2):e1920294. About Therapeutic Focus Our Medicine Careers & Culture Investors & Media Contact Us Terms of Use Transparency Privacy Cookies U.S. Consumer Health Privacy Manage Cookie Preferences Your Privacy Choices © 2026 Madrigal Pharmaceuticals, Inc. All rights reserved. The information on this website is intended for residents of the United States only. Madrigal Patient Support is a registered trademark of Madrigal Pharmaceuticals, Inc. US-CORP-MDGL-00002 You are now leaving madrigalpharma.com. By clicking this link you will be redirected to a website that is neither owned nor controlled by Madrigal. Madrigal is not responsible for the content or services of this site. Continue Stay Here

One-line Summary

Madrigal Pharmaceuticals has developed the first FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH), addressing a critical unmet need in progressive liver disease.

Decision Bullets

Expected: 3–5 bullets.

Scientific Summary: MASH is a progressive liver disease with few treatment options; Madrigal's FDA-approved medicine represents a breakthrough targeting liver fibrosis.
Evidence Gaps: Long-term efficacy and safety data beyond initial FDA approval remain limited; broader population effectiveness needs study.
Medical Insights: Early intervention to reverse fibrosis may prevent complications like cirrhosis and liver failure, improving patient prognosis.
Stakeholder Considerations: Patients, clinicians, and payers require education on MASH severity and new therapeutic options; advocacy groups can aid awareness.
Next Steps: Conduct real-world outcome studies, expand patient access programs, and continue research for adjunctive or combination therapies.

Mind Map

mindmap
  root((MASH Treatment))
    Research
      - First FDA-approved therapy
      - Focus on fibrosis reversal
    Disease
      - Metabolic dysfunction-associated steatohepatitis
      - Leads to cirrhosis, liver failure
      - Leading liver transplant cause
    Evidence Gaps
      - Long-term outcomes
      - Population diversity
    Medical Impact
      - Early intervention benefits
      - Prevents severe complications
    Stakeholders
      - Patients
      - Clinicians
      - Payers
      - Advocates
    Next Steps
      - Real-world studies
      - Patient access
      - Ongoing research

If needed, use the in-page "View source" button on the job detail page to see the raw mind map.

Key Clues

MASH is a progressive liver disease with high unmet clinical need
Leads to fibrosis, cirrhosis, liver failure, and liver cancer
First FDA-approved treatment for MASH developed by Madrigal
MASH is the leading cause of liver transplantation in women in the US
Goal to halt or reverse liver scarring and resolve MASH

Tag Intelligence

No inferred domain yet.

No canonical tags yet.

View Tag Insights

Tool Summary

Low support: fewer than 3 cited claims.

Citations: 0

No citations available yet.

No risk flags detected.